Cutaneous viral infections in HIV-infected individuals

Clinics in Dermatology

Volumn 18, Issue 4, 2000, Pages 423-432

  Yen Moore, Angela ^a   Straten, Melody Vander ^a   Carrasco, Daniel ^a   Evans, Tanya Y ^a   Tyring, Stephen K ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; DEOXYCYTIDINE PHOSPHATE; FAMCICLOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; INTERFERON; PODOPHYLLIN; PROTEINASE INHIBITOR; VALACICLOVIR; VIDARABINE;

EPSTEIN BARR VIRUS; GENITAL HERPES; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; POXVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; WART VIRUS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; HERPESVIRIDAE INFECTIONS; HUMAN; PAPILLOMAVIRUS, HUMAN; PAPOVAVIRIDAE INFECTIONS; POXVIRIDAE INFECTIONS; SKIN DISEASES, VIRAL; TUMOR VIRUS INFECTIONS;

EID: 0033829470     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(99)00137-6     Document Type: Review

References (98)

1. Safran S., Ashley R., Houlihan C., et al. Clinical and serological features of herpes simplex virus infection in patients with AIDS. AIDS. 5:1991;1107-1110.
2. Corey L., Spear P.G. Infections with herpes simplex viruses (part II). N Engl J Med. 314:1986;749-756.
3. Siegal F.P., Lopez C., Hammer G.S., et al. Severe acquired immunodeficiency in male homosexuals manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med. 305:1981;1439-1444.
4. Norris S.A., Kessler H.A., Fife K.H. Severe progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS (letter). J Infect Dis. 157:1988;209-210.
5. Zimmerli W., Bianchi L., Goudat F., et al. Disseminated herpes simplex type 2 in systemic candida infection in a patient with previous asymptomatic human immunodeficiency virus infection (letter). J Infect Dis. 157:1988;597-598.
6. Marks G.L., Nolan P.E., Erlich K.S., et al. Mucocutaneous dissemination of acyclovir-resistant herpes simplex virus in a patient with AIDS. Rev Infect Dis. 11:1989;474-476.
7. Simonson J.N., Cameron W.D., Gakenya M.N., et al. Human immunodeficiency virus infection among men with sexually transmitted diseases Experience from a center in Africa . N Engl J Med. 319:1988;274-278.
8. Stamm W.E., Hansfield H.H., Rompalo A.M., et al. The association between genital ulcerative disease and acquisition of HIV infection in homosexual men. JAMA. 260:1988;1429-1433.
9. Shacker T., Ryncarz A., Goddard J., et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1 infected men. JAMA. 280:1998;61-66.
10. Mole L., Ripich S., Margolis D., et al. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis. 176:1997;766-770.
11. Friedman-Kien A.E., LaFleur F.L., Gendler E.C., et al. Herpes zoster A possible early clinical sign for development of acquired immunodeficiency syndrome in high-risk individuals . J Am Acad Dermatol. 14:1986;1023-1028.
12. Jura E., Chadwick E.G., Josephs H.S., et al. Varicella zoster virus infections in children infected with human immunodeficiency virus. Pediatr Infect Dis J. 8:1989;856-890.
13. Janier M., Hilion B., Baccard M., et al. Chronic varicella zoster infection in acquired immunodeficiency syndrome (letter). J Am Acad Dermatol. 18:1988;584-585.
14. Cohen P.R., Beltranny V.P., Grossman M.E. Disseminated herpes zoster in patients with immunodeficiency virus infection. Am J Med. 84:1988;1076-1080.
15. Jacobson M.A., Berger T.G., Fikrig S., et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 112:1990;187-191.
16. Reichart P.S.A., Langford A., Gelderblom H.R., et al. Oral hairy leukoplakia Observations in 95 cases and review of the literature . J Oral Pathol Med. 18:1989;410-415.
17. Greenspan D., Greenspan J.S., Overby G., et al. Risk factors for rapid progression from hairy leukoplakia to AIDS A nested case-control study . J Acquir Immune Defic Syndr. 4:1991;652-658.
18. Greenspan J.S., Greenspan D., Lenette E.T., et al. Replication of Epstein-Barr virus within epithelial cells of oral "hairy" leukoplakia and AIDS-associated lesion. N Engl J Med. 313:1985;1564-1571.
19. Gaglioti D., De Pietro M., et al. Oral hairy leukoplakia Clinical appearance and treatment results (abstract) . Fifth International Conference on AIDS. Montreal, June 4-9. 473:1989.
20. Klatt E.C., Shibata D. Cytomegalovirus infection in the acquired immunodeficiency syndrome. Arch Pathol Lab Med. 112:1988;540-544.
21. Minars N., Silverman J.F., Escobar N.R., et al. Fatal cytomegalic inclusion disease Associated skin manifestations in a renal transplant patient . Arch Dermatol. 113:1977;1569-1571.
22. Muehler-Stamou A., Sen H.J., Emodi G. Epidermolysis in a case of severe cytomegalovirus infection. BMJ. 3:1974;609-611.
23. Chang Y., Cesarman E., Pessin M.S., et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 266:1994;1865-1869.
24. Rady P.L., Yen A., Rollefson J.L., et al. Herpesvirus-like DNA sequences in Kaposi's and non-Kaposi's sarcoma skin lesions of transplant patients. Lancet. 345:1995;1339-1340.
25. Evans T.Y., Tyring S.K. Advances in antiviral therapy in dermatology. Dermatol Therapy. 16:1998;409-420.
26. Wagstaff A.J., Faulds D., Goak L. Acyclovir, a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 47:1994;153-205.
27. Goldberg L.H., Kaufman R., Kurtz T.O., et al. The acyclovir study group. Long-term suppression of recurrent genital herpes with acyclovir A 5-year benchmark . Arch Dermatol. 129:1993;582-587.
28. Perrin L., Hirschel B. Combination therapy in primary HIV infection. Antiviral Res. 29:1996;87-89.
29. Wald A., Zeh J., Barnum G., et al. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med. 124:1996;8-15.
30. Huff JC, Drucker JL, Clemmer A, et al. Effect of oral acyclovir on pain resolution in herpes zoster. A reanalysis. J Med Virol 1993.
31. Saltzman R., Jurewicz R., Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother. 38:1994;2454-2457.
32. Heng M.C.Y., Heng S.Y. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus 1. Lancet. 343:1994;255-258.
33. Stanley S., Ostrowski M., Justement J. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med. 334:1996;1222-1230.
34. Schacker T, Lu H, Zeh J, et al. HSV suppression is associated with a significant decrease in plasma levels of HIV. Fifth Conference on Retroviruses and Opportunistic Infections, Alexandria, VA, 1998. Abstract 260.
35. Weller S., Blum M.R., Doucette M. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 54:1993;595-605.
36. Lawrence A, Bell A. Valaciclovir for prevention of recurrent herpes virus infection in HIV-infected individuals - a double blind control trial. Eighth European Congress of Clinical Microbiology and Infectious Diseases. Abstract, May 25-28, 1997, Lausanne, Switzerland.
37. Jackson J.L., Gibbons R., Meyer G., et al. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. Arch Intern Med. 157:1997;909-912.
38. Herne K., Cirelli R., Lee P., et al. Advances in antiviral therapy. Curr Opin Dermatol. 3:1996;195-201.
39. Thandi A., Tyring S.K. Newer aspects of herpesvirus infections. Dahl M.V. Current opinions in dermatology. 1997;42-50 Rapid Science Publishers, Philadelphia.
40. Tyring S., Barbarash R.A., Nahlik J., et al. Famciclovir for the treatment of acute herpes zoster Effects on acute disease and postherpetic neuralgia . Ann Intern Med. 123:1995;89-96.
41. Schacker T., Hu H.-I., Koelle D.M., et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. Ann Intern Med. 128:1998;21-28.
42. Reyes M, Graber J, Reeves W. Acyclovir resistant HSV: Preliminary results from a national surveillance system. International Conference on Emerging Infectious Diseases, Abstract, March 8-11, 1998, Atlanta, GA.
43. Burnside A, Preston A, Crann R, et al., and the Famciclovir Genital HSV in HIV Study Group. Famciclovir for suppression of recurrent genital herpes in HIV-infected patients. IDSA, Abstract, November 13, 1998, Denver, Colorado.
44. Birch C., Tachedjian G., Doherty R. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J Infect Dis. 162:1988;731-734.
45. Wasserheit J.N. Epidemiological synergy Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases . Sex Transm Dis. 29:1992;61-77.
46. Chatis P., Miller C., Schrager L. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med. 320:1989;297-300.
47. Youle M., Hawkins D., Collins P. Acyclovir-resistant herpes in AIDS patients treated with Foscarnet. Lancet. 2:1988;341-342.
48. Erlich K., Mills J., Chatis P. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med. 320:1989;293-296.
49. Safrin S., Assaykeen T. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients Preliminary data . J Infect Dis. 161:1990;1078-1084.
50. Lalezari J., Schaacker T., Feinberg J., et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis. 176:1997;892-898.
51. Kessler H.A., Benson C.A., Urbanski P. Regression of oral hairy leukoplakia during treatment with azidothymidine. Ann Intern Med. 148:1988;2496-2497.
52. Schofer H., Ochsendorf F.R., Elm E.B., et al. Treatment of oral hairy leukoplakia in AIDS patients with vitamin A acid (topically) or acyclovir (systemically) (letter). Dermatologica. 174:1987;150-151.
53. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl) guanine in patients with AIDS and other immunodeficiencies. N Engl J Med. 314:1986;801-805.
54. Zabawski E.J. Jr, Cockerell C.J. Topical and intralesional cidofovir A review of pharmacology and therapeutic effects . J Am Acad Dermatol. 39:1998;741-745.
55. De Clercq E. Therapeutic potential of cidofovir (HPMPC, Vistide) for the treatment of DNA virus (ie, herpes-, papova-, pox- and adenovirus) infections. Verh K Acad Geneeskd Belg. 58:1996;19-47.
56. Palefsky J. Human papillomavirus-associated malignancies in HIV-positive men and women. Curr Opin Oncol. 7:1995;437-441.
57. Klein R.S., Ho G.Y.F., Vermund S.H., et al. Risk factors for squamous intraepithelial lesions on Pap smear in women at risk for human immunodeficiency virus infection. J Infect Dis. 170:1994;1404-1409.
58. Palefsky J.M., Shiboski S., Moss A. Risk factors for anal human papillomavirus infection and anal cytologic abnormalities in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr. 7:1994;599-606.
59. Williams A.B., Darragh T.M., Vranizan K., et al. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol. 83:1994;205-211.
60. Spinillo A., Tenti P., Zappatore R., et al. Prevalence, diagnosis and treatment of lower genital neoplasia in women with human immunodeficiency virus infection. Eur J Obstet Gynecol Reprod Biol. 43:1992;235-241.
61. Sun X., Ellerbrock T., Lungu O., et al. Human papillomavirus infection in human immunodeficiency virus-seropositive women. Obstet Gynecol. 85:1995;680-686.
62. Seck A.C., Faye M.A., Critchlow C.W., et al. Cervical intraepithelial neoplasia and human papillomavirus infection among Senegalese women seropositive for HIV-1 or HIV-2 or seronegative for HIV. Int J STD AIDS. 5:1994;189-193.
63. Petry K.U., Kochel H., Bode U., et al. Human papillomavirus is associated with the frequent detection of warty and basaloid high-grade neoplasia of the vulva and cervical neoplasia among immunocompromised women. Gynecol Oncol. 60:1996;30-34.
64. Chirgwin K.D., Feldman J., Augenbraun M., et al. Incidence of venereal warts in human immunodeficiency virus-infected and uninfected women. J Infect Dis. 172:1995;235-238.
65. Tweddel G., Heller P., Cunnane M., et al. The correlation between HIV seropositivity, cervical dysplasia, and HPV subtypes 6/11, 16/18, 31/33/35. Gynecol Oncol. 52:1994;161-164.
66. Breese P.L., Judson F.N., Penley K.A., et al. Anal human papillomavirus infection among homosexual and bisexual men Prevalence of type-specific infection and association with human immunodeficiency virus . Sex Transm Dis. 22:1995;7-14.
67. Bernard C., Mougin C., Madoz L., et al. Viral co-infections in human papillomavirus-associated anogenital lesions according to the serostatus for the human immunodeficiency virus. Int J Cancer. 52:1992;731-737.
68. Garzetti G.G., Ciavattini A., Butini L., et al. Cervical dysplasia in HIV-seropositive women Role of human papillomavirus infection and immune status . Gynecol Obstet Invest. 40:1995;52-56.
69. Vernon S.D., Reeves W.C., Clancy K.A., et al. A longitudinal study of human papillomavirus DNA detection in human immunodeficiency virus type 1-seropositive and -seronegative women. J Infect Dis. 169:1994;1108-1112.
70. Stratton P., Ciacco K.H. Cervical neoplasia in the patient with HIV infection. Curr Opin Obstet Gynecol. 6:1994;86-91.
71. Baker D.A. Management of the female HIV-infected patient. AIDS Res Hum Retroviruses. 10:1994;935-938.
72. Ho G.Y.F., Burk R.D., Fleming I., et al. Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression. Int J Cancer. 56:1994;788-792.
73. Critchlow C.W., Surawicz C.M., Holmes K.K., et al. Prospective study of high-grade anal squamous intraepithelial neoplasia in a cohort of homosexual men Influence of HIV infection, immunosuppression and human papillomavirus infection . AIDS. 9:1995;1255-1262.
74. Bryan J.T., Stoler M.H., Tyring S.K., et al. High-grade dysplasia in genital warts from patients infected with the human immunodeficiency virus. J Med Virol. 54:1998;69-73.
75. Del Mistro A., Insacco E., Cinel A., et al. Human papillomavirus infections of the genital region in human immunodeficiency virus seropositive women Integration of type 16 correlates with rapid progression . Eur J Gynaecol Oncol. 15:1994;50-58.
76. Von Krogh G., Wilkstrom A., Syrjanen K., et al. Anal and penile condylomas in HIV-negative and HIV-positive men Clinical, histological and virological characteristics correlated to therapeutic outcome . Acta Derm Venereol. 75:1995;470-474.
77. Johnson J.C., Bumett A.F., Willet G.D., et al. High frequency of latent and clinical human papillomavirus cervical infections in immunocompromised human immunodeficiency virus-infected women. Obstet Gynecol. 79:1992;321-327.
78. Wright T.C., Ellerbrock T.V., Chiasson M.A., et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus Prevalence, risk factors, and validity of Papanicolaou smears . Obstet Gynecol. 84:1994;591-597.
79. Arany I., Tyring S.K. Systemic immunosuppression by HIV infection influences HPV transcription and thus local immune responses in condyloma acuminatum. Int J STD AIDS. 9:1998;268-271.
80. Spinillo A., Tenti P., Zappatore R., et al. Langerhans' cell counts and cervical intraepithelial neoplasia in women with human immunodeficiency virus infection. Gynecol Oncol. 48:1993;210-213.
81. Arany I., Tyring S.K. Immunodeficiency in condylomas is associated with HPV expression (abstract). J Invest Dermatol. 106:1996;913.
82. Arany I., Evans T., Tyring S.K. Tissue-specific HPV expression and downregulation of local immune response in condyloma from HIV-seropositive individuals. Sex Transm Inf. 74:1998;349-353.
83. Vernon S.D., Hart C.E., Reeves W.C., et al. The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Res. 27:1993;133-145.
84. Tornosello M.L., Buonaguro F.M., Beth-Giraldo E., et al. Human immunodeficiency virus type-1 tat gene enhances human papillomavirus early gene expression. Intervirology. 36:1993;57-64.
85. Peterson C.S., Weismann K. Quercetin and kaempherol An argument against the use of podophyllin? Genitourin Med. 71:1995;92-93.
86. Ziegler B.L., Thomas C.A., Meier T., et al. Generation of infectious retrovirus aerosol through medical laser irradiation. Lasers Surg Med. 22:1998;37-41.
87. Sawchuk W.S., Weber P.J., Lowy D.R., et al. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation Detection and protection . J Am Acad Dermatol. 21:1989;41-49.
88. Rockley P.F., Tyring S.K. Interferons alpha, beta, and gamma therapy of anogenital human papillomavirus infections. Pharmacol Ther. 65:1995;265-287.
89. Semprini A.E., Stillo A., Marcozi S., et al. Treatment with interferon for genital HPV in HIV-positive and HIV-negative women. Eur J Obstet Gynecol Reprod Biol. 53:1994;135-137.
90. Tyring S.K., Arany I., Stanley M.A., et al. A molecular study of condylomata acuminata clearance during treatment with imiquimod A randomized, double-blind, vehicle-controlled study . J Infect Dis. 178:1998;551-555.
91. Edwards L., Ferenczy A., Eron L., et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol. 134:1998;25-30.
92. Conant M.A. Immunomodulatory therapy in the management of viral infections in patients with HIV infection. J Am Acad Dermatol. 43:2000;S27-S30.
93. Lalezari JP, Stagg RJ, Jaffe HS, et al. A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC). In: Mills J, Corey L, editors. Antiviral chemotherapy. New York: Plenum Publishing, 1996.
94. Tyring SK, Douglas J, Schacker T, et al. A phase II study of Cidofovir topical gel for refractory condyloma acuminatum in patients with HIV infection. 55th Annual Meeting of the American Academy of Dermatology, March 21-26, 1997, San Francisco, California. Abstract p. 296.
95. Berger T.G., Greene I. Bacterial, viral, fungal and parasitic infections in HIV disease and AIDS. Dermatol Clin. 3:1991;465-492.
96. Meadows K.P., Tyring S.K., Pavia A.T., et al. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol. 133:1997;987-990.
97. Torok T.J. Parvovirus and human disease. Adv Intern Med. 37:1992;431-455.
98. Coldiron B.M., Freeman R.G., Beaudoing D.L. Isolation of adenovirus from a granuloma annulare-like lesion in the acquired immunodeficiency syndrome-related complex. Arch Dermatol. 124:1988;654-655.